

[REGISTER YOUR INTEREST HERE](#)

QUEENSLAND FAST FACTS

5 INTERNATIONAL PASSAGE AIRPORTS

240 DOMESTIC and **30** INTERNATIONAL from **3** DESTINATIONS per week into Gold Coast Airport

1,400 DOMESTIC and **300** INTERNATIONAL from **35** DESTINATIONS per week into Brisbane Airport

42,000 HOTEL ROOMS on the Gold Coast

\$166 USD Average Daily Rate (Source: Trivago 2026)

First convention centre in the world to become **EARTHCHECK PLATINUM CERTIFIED**

5.7 MILLION Population

77°F Average daily temperature in **October**

300 DAYS of sunshine annually* (*average)

\$3 USD for **3 days** of unlimited public transport

Host of the **2032** OLYMPIC AND PARALYMPIC GAMES

Home of the **WORLD'S OLDEST** LIVING CULTURE

OUR CAPABILITIES

- Biotechnology - Therapeutics and Diagnostics
- Biotechnology - R&D Services
- Biotechnology - Other
- Pharma - Integrated
- Medical Technology
- Digital Health
- Professional Services and Consulting
- Public/Non-Profit Organisations/Medical Facilities
- Supplier and Engineering
- Tropical Health
- Clinical Trials



- Boggo Road Innovation Precinct
- Sunshine Coast Precinct / Centre for Bioinnovation
- The Gold Coast Health and Knowledge Precinct
- Herston Health Precinct
- Springfield BioPark

QUEENSLAND'S BIOMEDICAL SECTOR

\$511B AUD GROSS STATE PRODUCT

43.5% REFUNDABLE R&D TAX INCENTIVE

LIFE SCIENCES

334 companies and

47,977 employed in sector

\$24.8B AUD MEDICAL RESEARCH FUTURE FUND to address emerging health needs

AUSTRALIA'S FIRST sovereign manufacturing capability **THORIUM-228**

8 RESEARCH FOCUSED UNIVERSITIES and **9** RESEARCH HOSPITALS

16 FREE TRADE AGREEMENTS

SHARED TIME ZONES or within **2HRS** of all major Asian markets

#1 RANKED HEALTH SYSTEM IN THE WORLD by the Commonwealth Fund in 2024

HOME TO MAJOR GLOBAL PLAYERS



BIOTECHNOLOGY IN QUEENSLAND

Queensland's biomedical ecosystem is the fastest growing of any state in Australia, growing by 74% between 2017-2022 and is a major hub for scientific discovery and translation in the Asia-Pacific region.

MAJOR PUBLIC CLINICAL TRIAL SITES

- Gold Coast University Hospital - [Read More](#)
- Logan Hospital - [Read More](#)
- Ipswich Hospital - [Read More](#)
- Royal Brisbane and Women's Hospital, Brisbane - [Read More](#)
- Princess Alexandra Hospital, Brisbane - [Read More](#)
- Queensland Children's Hospital, Brisbane - [Read More](#)
- The Prince Charles Hospital, Brisbane - [Read More](#)
- Queen Elizabeth II Jubilee Hospital, Brisbane - [Read More](#)
- Redcliffe Hospital - [Read More](#)
- Caboolture Hospital - [Read More](#)
- Sunshine Coast University Hospital - [Read More](#)
- Townsville University Hospital - [Read More](#)
- Mackay Base Hospital - [Read More](#)
- Cairns Hospital - [Read More](#)

MAJOR GOVERNMENT INVESTMENTS

In May 2026, the Queensland Government announced a \$15.25 million investment to support AdvancCell to establish Australia's first sovereign manufacturing capability for Thorium-228, the critical upstream isotope used in next-generation targeted alpha therapies to treat cancer. The project will make Queensland one of the only jurisdictions in the world capable of producing Thorium-228 at commercial scale and contribute to the development of a secure domestic supply chain for radioisotopes used in advanced cancer treatments.

QUEENSLAND'S CAPABILITIES

VACCINE DEVELOPMENT:

Globally adopted cervical cancer preventative, Gardasil

Millions of lives will be saved from cervical cancer by the Human Papilloma Virus (HPV) vaccine [Gardasil](#) that was developed at the University of Queensland. The vaccine first started to be developed in the 1990s and since it was released in 2006, there are over 200 million doses of the vaccine distributed in 130 countries.

AI-ENABLED HEALTHCARE:

World first wearable sensors clinically proven in Queensland

[WearOptimo's Microwearable](#) technology is the world's only wearable that effectively monitors hydration. The small, sticker-like patches use artificial intelligence to deliver real-time health monitoring without invasive procedures. Hydration monitoring is critical for industries such as defence, mining and sports, where dehydration and heat stress pose serious risks but the potential applications could extend even further to transform how we manage life-threatening conditions like heart failure and sepsis.

TELEMEDICINE:

Queensland led Australian Teletrials Program

The [Australian Teletrials Program](#) leverages telehealth and digital infrastructure to bring over 140 clinical trials to 3,000+ people at 416 rural, regional and remote community sites, dispelling the myth that clinical trial delivery can only occur in major city hospitals. This innovative model enhances recruitment, reduces patient burden and strengthens trial diversity while maintaining GCP-compliant oversight and governance.

INFECTIOUS DISEASES:

World-first chlamydia vaccine backed by \$280 million Translation Science Hub

Global healthcare company Sanofi has partnered with the Queensland Government and the University of Queensland to establish a world-first research centre, the [Translational Science Hub](#) in Brisbane and are creating a world-first human chlamydia vaccine. In March 2025, a [vaccine candidate was granted](#) FDA fast-track designation and trials are currently underway. The aim is to address chlamydia infection which can contribute to pelvic inflammatory diseases in women, leading to pregnancy complications or infertility.

HEART AND STROKE:

Groundbreaking funnel web spider venom found in Queensland island to reverse heart attack and stroke damage

University of Queensland researchers have discovered a new molecule in the venom of the [K'gari Island funnel-web spider](#) that has the potential to become a break-through drug that prevents injuries to heart cells during heart attacks and treating stroke patients. Animal testing is currently underway to provide results for regulatory approval to begin clinical trials on humans.

IMMUNOLOGY AND CANCER:

World-first clinical trial combination therapy to treat breast cancer

The Queensland Institute of Medical Research (QIMR) Berghofer scientists in collaboration with Australian drug development company Kazia Therapeutics are testing paxalisib in combination with immunotherapy for metastatic [triple-negative breast cancer](#). The multi-centre, open label phase 1b study will enrol 24 patients from leading cancer treatment centres in Queensland including the Royal Brisbane and Women's Hospital and provide combination therapy to participants for up to 12 months.

DEDICATED GOVERNMENT INDUSTRY SUPPORT



State Development,
Infrastructure and Planning



Queensland
Health

